Menu
Recruiting NCT06504225

EVEROLD LONG TERM FOLLOW-UP

— Observational Transplant; Complication, Failure

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Transplant; Complication, Failure. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Long-term Evaluation of the Value of Using an MTor Inhibitor (everolimus) for the Minimisation of Anticalceurins in Old-for-old Kidney Transplantation

Overview

Long Term Follow up of EVEROLD study

Primary outcome measures

  • Patient survival [Time frame: up to 12 years]
  • Graft survival [Time frame: up to 12 years]
Secondary outcome measures (6)
  • Rejection rate [Time frame: up to 12 years]
  • Infection rate [Time frame: up to 12 years]
  • Major cardiovascular events [Time frame: up to 12 years]
  • Cancer rate [Time frame: up to 12 years]
  • Hospitalization [Time frame: up to 12 years]
  • eGFR [Time frame: up to 12 years]

Eligibility criteria

Inclusion criteria

  • Informed patients participating to the EVEROLD study
  • Patient having completed the EVEROLD M12 follow-up visit
  • Patient agreeing to participate in the observational study

Exclusion criteria

  • Opposition to the use his medical data
  • Patient under legal protection

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

France · 14 centers
  • Chu Amiens — Amiens
  • CHU Bordeaux — Bordeaux
  • Chu Brest — Brest
  • CHU Lille — Lille
  • CHU Limoges — Limoges
  • CHU Nice Pasteur 2 — Nice
  • CHU Nice — Nice
  • Hôpital Necker — Paris
  • … and 6 more centers

Identifiers

NCT: NCT06504225 · 29BRC23.0069 - Everold FUP

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗